Nautilus Biotechnology logo

Nautilus Biotechnology

nautilus.bio

Nautilus Biotechnology develops the Voyager platform, which uses Iterative Mapping technology for accurate single-molecule quantification of proteins and proteoforms. Its products are designed for researchers in drug development, biomarker discovery, and exploratory biology to provide comprehensive views of the proteome and support deep biological insights. The organization aims to revolutionize biomedicine by unlocking the complexity of the proteome to positively impact global health.

Facts

HQ
Seattle
Sectors
Biotechnology Research
Founded
2016
Employees
148
Stage
Public
Members see funding amounts.
.
Founders
Sujal Patel, Parag Mallick, PhD

Is this your organization? Claim it

Nautilus Biotechnology Reports Q3 2026: $0.2M Revenue, Nature Methods Paper, $6M ARPA-H SEEDS Award Expected

Nautilus Biotechnology reported Q3 2026 results highlighting a Nature Methods paper validating its Iterative Mapping on the Voyager platform, progress on oncology proteoform assays and a pipeline aiming for 20 assays by mid-2028, and expects up to $6 million from an ARPA-H–funded consortium (SEEDS). Revenue for the quarter was $0.2 million, primarily from grant income.

See all 41 news stories about Nautilus Biotechnology.

People

See all 4
  • Sujal Patel
    Sujal Patel Executive Officer, Director, Founder & CEO
  • Parag Mallick Founder & Chief Scientist
  • Anna Mowry Executive, Chief Financial Officer

Online